|
1
|
Brown TA and McKnight SL: Specificities of
protein-protein and protein-DNA interaction of GABP alpha and two
newly defined ets-related proteins. Genes Dev. 6:2502–2512. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monte D, Coutte L, Baert JL, Angeli I,
Stehelin D and de Launoit Y: Molecular characterization of the
ets-related human transcription factor ER81. Oncogene. 11:771–779.
1995.PubMed/NCBI
|
|
3
|
Janknecht R: Analysis of the
ERK-stimulated ETS transcription factor ER81. Mol Cell Biol.
16:1550–1556. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei GH, Badis G, Berger MF, Kivioja T,
Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al:
Genome-wide analysis of ETS-family DNA-binding in vitro and in
vivo. EMBO J. 29:2147–2160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hollenhorst PC, McIntosh LP and Graves BJ:
Genomic and biochemical insights into the specificity of ETS
transcription factors. Annu Rev Biochem. 80:437–471. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oh S, Shin S and Janknecht R: ETV1, 4 and
5: An oncogenic subfamily of ETS transcription factors. Biochim
Biophys Acta. 1826:1–12. 2012.PubMed/NCBI
|
|
7
|
Arber S, Ladle DR, Lin JH, Frank E and
Jessell TM: ETS gene Er81 controls the formation of functional
connections between group Ia sensory afferents and motor neurons.
Cell. 101:485–498. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kucera J, Cooney W, Que A, Szeder V,
Stancz-Szeder H and Walro J: Formation of supernumerary muscle
spindles at the expense of Golgi tendon organs in ER81-deficient
mice. Dev Dyn. 223:389–401. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sedy J, Tseng S, Walro JM, Grim M and
Kucera J: ETS transcription factor ER81 is required for the
pacinian corpuscle development. Dev Dyn. 235:1081–1089. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shekhar A, Lin X, Liu FY, Zhang J, Mo H,
Bastarache L, Denny JC, Cox NJ, Delmar M, Roden DM, et al:
Transcription factor ETV1 is essential for rapid conduction in the
heart. J Clin Invest. 126:4444–4459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Papoutsopoulou S and Janknecht R:
Phosphorylation of ETS transcription factor ER81 in a complex with
its coactivators CREB-binding protein and p300. Mol Cell Biol.
20:7300–7310. 2000.PubMed/NCBI
|
|
12
|
Bosc DG, Goueli BS and Janknecht R:
HER2/Neu-mediated activation of the ETS transcription factor ER81
and its target gene MMP-1. Oncogene. 20:6215–6224. 2001.PubMed/NCBI
|
|
13
|
Wu J and Janknecht R: Regulation of the
ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1
and protein kinase A. J Biol Chem. 277:42669–42679. 2002.PubMed/NCBI
|
|
14
|
Xie L, Gazin C, Park SM, Zhu LJ, Debily
MA, Kittler EL, Zapp ML, Lapointe D, Gobeil S, Virbasius CM and
Green MR: A synthetic interaction screen identifies factors
selectively required for proliferation and TERT transcription in
p53-deficient human cancer cells. PLoS Genet. 8:e10031512012.
|
|
15
|
Janknecht R: Regulation of the ER81
transcription factor and its coactivators by mitogen- and
stress-activated protein kinase 1 (MSK1). Oncogene. 22:746–755.
2003.PubMed/NCBI
|
|
16
|
Goel A and Janknecht R:
Acetylation-mediated transcriptional activation of the ETS protein
ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol. 23:6243–6254.
2003.PubMed/NCBI
|
|
17
|
Baert JL, Monte D, Verreman K, Degerny C,
Coutte L and de Launoit Y: The E3 ubiquitin ligase complex
component COP1 regulates PEA3 group member stability and
transcriptional activity. Oncogene. 29:1810–1820. 2010.PubMed/NCBI
|
|
18
|
Vitari AC, Leong KG, Newton K, Yee C,
O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al: COP1
is a tumour suppressor that causes degradation of ETS transcription
factors. Nature. 474:403–406. 2011.PubMed/NCBI
|
|
19
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648.
2005.PubMed/NCBI
|
|
20
|
Attard G, Clark J, Ambroisine L, Mills IG,
Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, et al:
Heterogeneity and clinical significance of ETV1 translocations in
human prostate cancer. Br J Cancer. 99:314–320. 2008.PubMed/NCBI
|
|
21
|
Shin S, Kim TD, Jin F, van Deursen JM,
Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G and Janknecht
R: Induction of prostatic intraepithelial neoplasia and modulation
of androgen receptor by ETS variant 1/ETS-related protein 81.
Cancer Res. 69:8102–8110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baena E, Shao Z, Linn DE, Glass K, Hamblen
MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, et al: ETV1
directs androgen metabolism and confers aggressive prostate cancer
in targeted mice and patients. Genes Dev. 27:683–698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomlins SA, Laxman B, Dhanasekaran SM,
Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et
al: Distinct classes of chromosomal rearrangements create oncogenic
ETS gene fusions in prostate cancer. Nature. 448:595–599. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim TD, Jin F, Shin S, Oh S, Lightfoot SA,
Grande JP, Johnson AJ, van Deursen JM, Wren JD and Janknecht R:
Histone demethylase JMJD2A drives prostate tumorigenesis through
transcription factor ETV1. J Clin Invest. 126:706–720. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kooistra SM and Helin K: Molecular
mechanisms and potential functions of histone demethylases. Nat Rev
Mol Cell Biol. 13:297–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berry WL and Janknecht R: KDM4/JMJD2
histone demethylases: Epigenetic regulators in cancer cells. Cancer
Res. 73:2936–2942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oh S, Shin S and Janknecht R: The small
members of the JMJD protein family: Enzymatic jewels or jinxes?
Biochim Biophys Acta Rev Cancer. 1871:406–418. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Whetstine JR, Nottke A, Lan F, Huarte M,
Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M and Shi
Y: Reversal of histone lysine trimethylation by the JMJD2 family of
histone demethylases. Cell. 125:467–481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klose RJ, Yamane K, Bae Y, Zhang D,
Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: The
transcriptional repressor JHDM3A demethylates trimethyl histone H3
lysine 9 and lysine 36. Nature. 442:312–316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shin S and Janknecht R: Diversity within
the JMJD2 histone demethylase family. Biochem Biophys Res Commun.
353:973–977. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim TD, Oh S, Lightfoot SA, Shin S, Wren
JD and Janknecht R: Upregulation of PSMD10 caused by the JMJD2A
histone demethylase. Int J Clin Exp Med. 9:10123–10134.
2016.PubMed/NCBI
|
|
32
|
Kim TD, Fuchs JR, Schwartz E, Abdelhamid
D, Etter J, Berry WL, Li C, Ihnat MA, Li PK and Janknecht R:
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon
cancer cells and identification of curcuminoids as JMJD2
inhibitors. Am J Transl Res. 6:236–247. 2014.PubMed/NCBI
|
|
33
|
Kim TD, Shin S, Berry WL, Oh S and
Janknecht R: The JMJD2A demethylase regulates apoptosis and
proliferation in colon cancer cells. J Cell Biochem. 113:1368–1376.
2012. View Article : Google Scholar
|
|
34
|
Lee HJ, Kim BK, Yoon KB, Kim YC and Han
SY: Novel inhibitors of lysine (K)-specific demethylase 4A with
anticancer activity. Invest New Drugs. 35:733–741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crawford HC, Fingleton B, Gustavson MD,
Kurpios N, Wagenaar RA, Hassell JA and Matrisian LM: The PEA3
subfamily of Ets transcription factors synergizes with
beta-catenin-LEF-1 to activate matrilysin transcription in
intestinal tumors. Mol Cell Biol. 21:1370–1383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Horiuchi S, Yamamoto H, Min Y, Adachi Y,
Itoh F and Imai K: Association of ets-related transcriptional
factor E1AF expression with tumour progression and overexpression
of MMP-1 and matrilysin in human colorectal cancer. J Pathol.
200:568–576. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoo J, Jeon YH, Cho HY, Lee SW, Kim GW,
Lee DH and Kwon SH: Advances in histone demethylase KDM3A as a
cancer therapeutic target. Cancers (Basel). 12:10982020. View Article : Google Scholar
|
|
38
|
Sui Y, Gu R and Janknecht R: Crucial
functions of the JMJD1/KDM3 epigenetic regulators in cancer. Mol
Cancer Res. Jun 30–2020.Epub ahead of print. View Article : Google Scholar
|
|
39
|
Uemura M, Yamamoto H, Takemasa I, Mimori
K, Hemmi H, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Doki Y
and Mori M: Jumonji domain containing 1A is a novel prognostic
marker for colorectal cancer: In vivo identification from hypoxic
tumor cells. Clin Cancer Res. 16:4636–4646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Yu B, Deng P, Cheng Y, Yu Y, Kevork
K, Ramadoss S, Ding X, Li X and Wang CY: KDM3 epigenetically
controls tumorigenic potentials of human colorectal cancer stem
cells through Wnt/β-catenin signalling. Nat Commun. 8:151462017.
View Article : Google Scholar
|
|
41
|
Peng K, Su G, Ji J, Yang X, Miao M, Mo P,
Li M, Xu J, Li W and Yu C: Histone demethylase JMJD1A promotes
colorectal cancer growth and metastasis by enhancing Wnt/β-catenin
signaling. J Biol Chem. 293:10606–10619. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li X, Oh S, Song H, Shin S, Zhang B,
Freeman WM and Janknecht R: A potential common role of the Jumonji
C domain-containing 1A histone demethylase and chromatin remodeler
ATRX in promoting colon cancer. Oncol Lett. 16:6652–6662.
2018.PubMed/NCBI
|
|
43
|
Dowdy SC, Mariani A and Janknecht R:
HER2/Neu- and TAK1-mediated up-regulation of the transforming
growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol
Chem. 278:44377–44384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mooney SM, Goel A, D'Assoro AB, Salisbury
JL and Janknecht R: Pleiotropic effects of p300-mediated
acetylation on p68 and p72 RNA helicase. J Biol Chem.
285:30443–30452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim TD, Shin S and Janknecht R: ETS
transcription factor ERG cooperates with histone demethylase KDM4A.
Oncol Rep. 35:3679–3688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oh S, Shin S, Lightfoot SA and Janknecht
R: 14-3-3 proteins modulate the ETS transcription factor ETV1 in
prostate cancer. Cancer Res. 73:5110–5119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Berry WL, Shin S, Lightfoot SA and
Janknecht R: Oncogenic features of the JMJD2A histone demethylase
in breast cancer. Int J Oncol. 41:1701–1706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim J, Shin S, Subramaniam M, Bruinsma E,
Kim TD, Hawse JR, Spelsberg TC and Janknecht R: Histone demethylase
JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res
Commun. 401:412–416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim TD, Oh S, Shin S and Janknecht R:
Regulation of tumor suppressor p53 and HCT116 cell physiology by
histone demethylase JMJD2D/KDM4D. PLoS One. 7:e346182012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Berry WL, Kim TD and Janknecht R:
Stimulation of β-catenin and colon cancer cell growth by the KDM4B
histone demethylase. Int J Oncol. 44:1341–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matthias P, Muller MM, Schreiber E,
Rusconi S and Schaffner W: Eukaryotic expression vectors for the
analysis of mutant proteins. Nucleic Acids Res. 17:64181989.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li X, Moon G, Shin S, Zhang B and
Janknecht R: Cooperation between ETS variant 2 and Jumonji
domain-containing 2 histone demethylases. Mol Med Rep.
17:5518–5527. 2018.PubMed/NCBI
|
|
54
|
Rossow KL and Janknecht R: The Ewing's
sarcoma gene product functions as a transcriptional activator.
Cancer Res. 61:2690–2695. 2001.PubMed/NCBI
|
|
55
|
Mooney SM, Grande JP, Salisbury JL and
Janknecht R: Sumoylation of p68 and p72 RNA helicases affects
protein stability and transactivation potential. Biochemistry.
49:1–10. 2010. View Article : Google Scholar
|
|
56
|
Knebel J, De Haro L and Janknecht R:
Repression of transcription by TSGA/Jmjd1a, a novel interaction
partner of the ETS protein ER71. J Cell Biochem. 99:319–329. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Goel A and Janknecht R: Concerted
activation of ETS protein ER81 by p160 coactivators, the
acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J
Biol Chem. 279:14909–14916. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Janknecht R and Hunter T: Activation of
the Sap-1a transcription factor by the c-Jun N-terminal kinase
(JNK) mitogen-activated protein kinase. J Biol Chem. 272:4219–4224.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang YL, Wang PW, Wang FS, Lin HY and
Huang YH: miR-29a modulates GSK3β/SIRT1-linked mitochondrial
proteostatic stress to ameliorate mouse non-alcoholic
steatohepatitis. Int J Mol Sci. 21:E68842020. View Article : Google Scholar
|
|
60
|
Lin X, Feng D, Li P and Lv Y: LncRNA
LINC00857 regulates the progression and glycolysis in ovarian
cancer by modulating the Hippo signaling pathway. Cancer Med. Sep
12–2020.Epub ahead of print. View Article : Google Scholar
|
|
61
|
Chen X, Liu X, Gao Y, Lin J, Liu X, Pang
X, Lin J and Chen L: Application of firefly luciferase (Luc) as a
reporter gene for the chemoautotrophic and acidophilic
Acidithiobacillus spp. Curr Microbiol. 77:3724–3730. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ou Y, Liao C, Li H and Yu G: LncRNA
SOX2OT/Smad3 feed-back loop promotes myocardial fibrosis in heart
failure. IUBMB Life. Sep 21–2020.Epub ahead of print. View Article : Google Scholar
|
|
63
|
Sims RJ III, Liss AS and Gottlieb PD:
Normalization of luciferase reporter assays under conditions that
alter internal controls. Biotechniques. 34:938–940. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shifera AS and Hardin JA: Factors
modulating expression of Renilla luciferase from control plasmids
used in luciferase reporter gene assays. Anal Biochem. 396:167–172.
2010. View Article : Google Scholar
|
|
65
|
Wu GQ, Wang X, Zhou HY, Chai KQ, Xue Q,
Zheng AH, Zhu XM, Xiao JY, Ying XH, Wang FW, et al: Evidence for
transcriptional interference in a dual-luciferase reporter system.
Sci Rep. 5:176752015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Repele A and Manu: Robust normalization of
luciferase reporter data. Methods Protoc. 2:622019. View Article : Google Scholar :
|
|
67
|
Shin S, Oh S, An S and Janknecht R: ETS
variant 1 regulates matrix metalloproteinase-7 transcription in
LNCaP prostate cancer cells. Oncol Rep. 29:306–314. 2013.
View Article : Google Scholar
|
|
68
|
Shin S, Bosc DG, Ingle JN, Spelsberg TC
and Janknecht R: Rcl is a novel ETV1/ER81 target gene upregulated
in breast tumors. J Cell Biochem. 105:866–874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Oh S, Shin S, Song H, Grande JP and
Janknecht R: Relationship between ETS transcription factor ETV1 and
TGF-β-regulated SMAD proteins in prostate cancer. Sci Rep.
9:81862019. View Article : Google Scholar
|
|
70
|
Oh S and Janknecht R: Histone demethylase
JMJD5 is essential for embryonic development. Biochem Biophys Res
Commun. 420:61–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
72
|
Sui Y, Li X, Oh S, Zhang B, Freeman WM,
Shin S and Janknecht R: Opposite roles of the JMJD1A interaction
partners MDFI and MDFIC in colorectal cancer. Sci Rep. 10:87102020.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Goueli BS and Janknecht R: Upregulation of
the catalytic telomerase subunit by the transcription factor ER81
and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol. 24:25–35. 2004.
View Article : Google Scholar :
|
|
74
|
Goueli BS and Janknecht R: Regulation of
telomerase reverse transcriptase gene activity by upstream
stimulatory factor. Oncogene. 22:8042–8047. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
DiTacchio L, Bowles J, Shin S, Lim DS,
Koopman P and Janknecht R: Transcription factors ER71/ETV2 and SOX9
participate in a positive feedback loop in fetal and adult mouse
testis. J Biol Chem. 287:23657–23666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Orlando G, Law PJ, Cornish AJ, Dobbins SE,
Chubb D, Broderick P, Litchfield K, Hariri F, Pastinen T, Osborne
CS, et al: Promoter capture Hi-C-based identification of recurrent
noncoding mutations in colorectal cancer. Nat Genet. 50:1375–1380.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hong Y, Downey T, Eu KW, Koh PK and Cheah
PY: A 'metastasis-prone' signature for early-stage mismatch-repair
proficient sporadic colorectal cancer patients and its implications
for possible therapeutics. Clin Exp Metastasis. 27:83–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Skrzypczak M, Goryca K, Rubel T, Paziewska
A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J:
Modeling oncogenic signaling in colon tumors by multidirectional
analyses of microarray data directed for maximization of analytical
reliability. PLoS One. 5:e130912010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Smith JJ, Deane NG, Wu F, Merchant NB,
Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al:
Experimentally derived metastasis gene expression profile predicts
recurrence and death in patients with colon cancer.
Gastroenterology. 138:958–968. 2010. View Article : Google Scholar
|
|
80
|
Xie N, Yao Y, Wan L, Zhu T, Liu L and Yuan
J: Next-generation sequencing reveals lymph node metastasis
associated genetic markers in colorectal cancer. Exp Ther Med.
14:338–343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang Y, Wei J, Zhang S, Li G, Zhang T, Yu
X, Chen H and Liu M: Overexpression of Wnt7α protein predicts poor
survival in patients with colorectal carcinoma. Tumour Biol.
36:8781–8787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Avgustinova A, Iravani M, Robertson D,
Fearns A, Gao Q, Klingbeil P, Hanby AM, Speirs V, Sahai E, Calvo F
and Isacke CM: Tumour cell-derived Wnt7a recruits and activates
fibroblasts to promote tumour aggressiveness. Nat Commun.
7:103052016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Nishioka M, Ueno K, Hazama S, Okada T,
Sakai K, Suehiro Y, Okayama N, Hirata H, Oka M, Imai K, et al:
Possible involvement of Wnt11 in colorectal cancer progression. Mol
Carcinog. 52:207–217. 2013. View Article : Google Scholar
|
|
85
|
He D, Yue Z, Liu L, Fang X, Chen L and Han
H: Long noncoding RNA ABHD11-AS1 promote cells proliferation and
invasion of colorectal cancer via regulating the miR-1254-WNT11
pathway. J Cell Physiol. 234:12070–12079. 2019. View Article : Google Scholar
|
|
86
|
Kaneda H, Arao T, Tanaka K, Tamura D,
Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y,
et al: FOXQ1 is overexpressed in colorectal cancer and enhances
tumorigenicity and tumor growth. Cancer Res. 70:2053–2063. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Abba M, Patil N, Rasheed K, Nelson LD,
Mudduluru G, Leupold JH and Allgayer H: Unraveling the role of
FOXQ1 in colorectal cancer metastasis. Mol Cancer Res.
11:1017–1028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Peng X, Luo Z, Kang Q, Deng D, Wang Q,
Peng H, Wang S and Wei Z: FOXQ1 mediates the crosstalk between
TGF-β and Wnt signaling pathways in the progression of colorectal
cancer. Cancer Biol Ther. 16:1099–1109. 2015. View Article : Google Scholar :
|
|
89
|
Liu JY, Wu XY, Wu GN, Liu FK and Yao XQ:
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation
in colorectal carcinoma. Am J Transl Res. 9:2207–2218.
2017.PubMed/NCBI
|
|
90
|
Möller P, Koretz K, Leithäuser F,
Brüderlein S, Henne C, Quentmeier A and Krammer PH: Expression of
APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in
normal and neoplastic colon epithelium. Int J Cancer. 57:371–377.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xiao W, Ibrahim ML, Redd PS, Klement JD,
Lu C, Yang D, Savage NM and Liu K: Loss of Fas expression and
function Is coupled with colon cancer resistance to immune
checkpoint inhibitor immunotherapy. Mol Cancer Res. 17:420–430.
2019. View Article : Google Scholar :
|
|
92
|
Park SJ, Kim HB, Kim J, Park S, Kim SW and
Lee JH: The oncogenic effects of p53-inducible gene 3 (PIG3) in
colon cancer cells. Korean J Physiol Pharmacol. 21:267–273. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer. Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Krieg AJ, Rankin EB, Chan D, Razorenova O,
Fernandez S and Giaccia AJ: Regulation of the histone demethylase
JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene
expression and tumor growth. Mol Cell Biol. 30:344–353. 2010.
View Article : Google Scholar
|
|
96
|
Zong Y, Xin L, Goldstein AS, Lawson DA,
Teitell MA and Witte ON: ETS family transcription factors
collaborate with alternative signaling pathways to induce carcinoma
from adult murine prostate cells. Proc Natl Acad Sci USA.
106:12465–12470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fan L, Peng G, Sahgal N, Fazli L, Gleave
M, Zhang Y, Hussain A and Qi J: Regulation of c-Myc expression by
the histone demethylase JMJD1A is essential for prostate cancer
cell growth and survival. Oncogene. 35:2441–2452. 2016. View Article : Google Scholar :
|
|
98
|
Wilson S, Fan L, Sahgal N, Qi J and Filipp
FV: The histone demethylase KDM3A regulates the transcriptional
program of the androgen receptor in prostate cancer cells.
Oncotarget. 8:30328–30343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fan L, Zhang F, Xu S, Cui X, Hussain A,
Fazli L, Gleave M, Dong X and Qi J: Histone demethylase JMJD1A
promotes alter-native splicing of AR variant 7 (AR-V7) in prostate
cancer cells. Proc Natl Acad Sci USA. 115:E4584–E4593. 2018.
View Article : Google Scholar
|
|
100
|
Tang DE, Dai Y, Fan LL, Geng XY, Fu DX,
Jiang HW and Xu SH: Histone demethylase JMJD1A promotes tumor
progression via activating Snail in prostate cancer. Mol Cancer
Res. 18:698–708. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ikeda H, Old LJ and Schreiber RD: The
roles of IFN gamma in protection against tumor development and
cancer immunoediting. Cytokine Growth Factor Rev. 13:95–109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mojic M, Takeda K and Hayakawa Y: The dark
side of IFN-ү: Its role in promoting cancer immunoevasion. Int J
Mol Sci. 19:892017. View Article : Google Scholar
|
|
103
|
Jung B, Staudacher JJ and Beauchamp D:
Transforming growth factor β superfamily signaling in development
of colorectal cancer. Gastroenterology. 152:36–52. 2017. View Article : Google Scholar
|
|
104
|
Jiao HL, Ye YP, Yang RW, Sun HY, Wang SY,
Wang YX, Xiao ZY, He LQ, Cai JJ, Wei WT, et al: Downregulation of
SAFB sustains the NF-κB pathway by targeting TAK1 during the
progression of colorectal cancer. Clin Cancer Res. 23:7108–7118.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Weng W, Okugawa Y, Toden S, Toiyama Y,
Kusunoki M and Goel A: FOXM1 and FOXQ1 are promising prognostic
biomarkers and novel targets of tumor-suppressive miR-342 in human
colorectal cancer. Clin Cancer Res. 22:4947–4957. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Bagati A, Bianchi-Smiraglia A, Moparthy S,
Kolesnikova K, Fink EE, Lipchick BC, Kolesnikova M, Jowdy P,
Polechetti A, Mahpour A, et al: Melanoma suppressor functions of
the carcinoma oncogene FOXQ1. Cell Rep. 20:2820–2832. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Nau MM, Brooks BJ, Battey J, Sausville E,
Gazdar AF, Kirsch IR, McBride OW, Bertness V, Hollis GF and Minna
JD: L-myc, a new myc-related gene amplified and expressed in human
small cell lung cancer. Nature. 318:69–73. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wu R, Lin L, Beer DG, Ellenson LH, Lamb
BJ, Rouillard JM, Kuick R, Hanash S, Schwartz DR, Fearon ER and Cho
KR: Amplification and overexpression of the L-MYC proto-onco-gene
in ovarian carcinomas. Am J Pathol. 162:1603–1610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Boutros PC, Fraser M, Harding NJ, de Borja
R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A,
Sabelnykova VY, et al: Spatial genomic heterogeneity within
localized, multifocal prostate cancer. Nat Genet. 47:736–745. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Huijbers IJ, Bin Ali R, Pritchard C,
Cozijnsen M, Kwon MC, Proost N, Song JY, de Vries H, Badhai J,
Sutherland K, et al: Rapid target gene validation in complex cancer
mouse models using re-derived embryonic stem cells. EMBO Mol Med.
6:212–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kim DW, Wu N, Kim YC, Cheng PF, Basom R,
Kim D, Dunn CT, Lee AY, Kim K, Lee CS, et al: Genetic requirement
for Mycl and efficacy of RNA Pol I inhibition in mouse models of
small cell lung cancer. Genes Dev. 30:1289–1299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Möröy T, Fisher P, Guidos C, Ma A,
Zimmerman K, Tesfaye A, DePinho R, Weissman I and Alt FW: IgH
enhancer deregulated expression of L-myc: Abnormal T lymphocyte
development and T cell lymphomagenesis. EMBO J. 9:3659–3666. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Chapman DL and Papaioannou VE: Three
neural tubes in mouse embryos with mutations in the T-box gene
Tbx6. Nature. 391:695–697. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sandbacka M, Laivuori H, Freitas E,
Halttunen M, Jokimaa V, Morin-Papunen L, Rosenberg C and Aittomaki
K: TBX6, LHX1 and copy number variations in the complex genetics of
Mullerian aplasia. Orphanet J Rare Dis. 8:1252013. View Article : Google Scholar
|
|
115
|
Wu N, Ming X, Xiao J, Wu Z, Chen X,
Shinawi M, Shen Y, Yu G, Liu J, Xie H, et al: TBX6 null variants
and a common hypomorphic allele in congenital scoliosis. N Engl J
Med. 372:341–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Verbitsky M, Westland R, Perez A, Kiryluk
K, Liu Q, Krithivasan P, Mitrotti A, Fasel DA, Batourina E, Sampson
MG, et al: The copy number variation landscape of congenital
anomalies of the kidney and urinary tract. Nat Genet. 51:117–127.
2019. View Article : Google Scholar :
|
|
117
|
Ren X, Yang N, Wu N, Xu X, Chen W, Zhang
L, Li Y, Du RQ, Dong S, Zhao S, et al: Increased TBX6 gene dosages
induce congenital cervical vertebral malformations in humans and
mice. J Med Genet. 57:371–379. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Takemoto T, Uchikawa M, Yoshida M, Bell
DM, Lovell-Badge R, Papaioannou VE and Kondoh H: Tbx6-dependent
Sox2 regulation determines neural or mesodermal fate in axial stem
cells. Nature. 470:394–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sadahiro T, Isomi M, Muraoka N, Kojima H,
Haginiwa S, Kurotsu S, Tamura F, Tani H, Tohyama S, Fujita J, et
al: Tbx6 induces nascent mesoderm from pluripotent stem cells and
temporally controls cardiac versus somite lineage diversification.
Cell Stem Cell. 23:382–395.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Saigusa S, Tanaka K, Toiyama Y, Yokoe T,
Okugawa Y, Ioue Y, Miki C and Kusunoki M: Correlation of CD133,
OCT4, and SOX2 in rectal cancer and their association with distant
recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Ong CW, Kim LG, Kong HH, Low LY, Iacopetta
B, Soong R and Salto-Tellez M: CD133 expression predicts for
non-response to chemotherapy in colorectal cancer. Mod Pathol.
23:450–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Neumann J, Bahr F, Horst D, Kriegl L,
Engel J, Luque RM, Gerhard M, Kirchner T and Jung A: SOX2
expression correlates with lymph-node metastases and distant spread
in right-sided colon cancer. BMC Cancer. 11:5182011. View Article : Google Scholar : PubMed/NCBI
|
